Iteos Therapeutics Stock Performance
| ITOS Stock | USD 7.07 0.09 1.29% |
The company retains a Market Volatility (i.e., Beta) of 0.54, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Iteos Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Iteos Therapeutics is expected to be smaller as well. At this point, Iteos Therapeutics has a negative expected return of -0.29%. Please make sure to check out Iteos Therapeutics' maximum drawdown, as well as the relationship between the daily balance of power and relative strength index , to decide if Iteos Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Iteos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 1.29 | Five Day Return (6.48) | Year To Date Return (10.51) | Ten Year Return (62.89) | All Time Return (62.89) |
1 | Technical Data - Stock Traders Daily | 12/04/2024 |
2 | Acquisition by Feltquate David of 47000 shares of Iteos Therapeutics subject to Rule 16b-3 | 12/06/2024 |
3 | iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical ... | 12/12/2024 |
4 | iTeos Therapeutics prsentiert vorlufige Daten der klinischen Studie A2A-005 sowie translationale und prklinische Daten zu Inupadenant auf dem ESMO-Kongress fr I... | 12/13/2024 |
5 | iTeos Therapeutics and Calidi Biotherapeutics Head-To-Head Review | 01/02/2025 |
6 | iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 01/08/2025 |
7 | iTeos Therapeutics Buy Rating Reaffirmed at HC Wainwright - MarketBeat | 01/16/2025 |
8 | We Think iTeos Therapeutics Needs To Drive Business Growth Carefully | 02/04/2025 |
9 | Acquisition by Davis Aaron I. of 24200 shares of Iteos Therapeutics at 16.32 subject to Rule 16b-3 | 02/07/2025 |
10 | ITOS stock touches 52-week low at 7.09 amid market challenges - MSN | 02/12/2025 |
| Begin Period Cash Flow | 285 M |
Iteos |
Iteos Therapeutics Relative Risk vs. Return Landscape
If you would invest 855.00 in Iteos Therapeutics on November 29, 2024 and sell it today you would lose (148.00) from holding Iteos Therapeutics or give up 17.31% of portfolio value over 90 days. Iteos Therapeutics is currently does not generate positive expected returns and assumes 2.3309% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Iteos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Iteos Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Iteos Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Iteos Therapeutics, and traders can use it to determine the average amount a Iteos Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1265
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ITOS |
Estimated Market Risk
| 2.33 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Iteos Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Iteos Therapeutics by adding Iteos Therapeutics to a well-diversified portfolio.
Iteos Therapeutics Fundamentals Growth
Iteos Stock prices reflect investors' perceptions of the future prospects and financial health of Iteos Therapeutics, and Iteos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Iteos Stock performance.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (4.17) % | ||||
| Current Valuation | (224.89 M) | ||||
| Shares Outstanding | 36.53 M | ||||
| Price To Earning | 50.50 X | ||||
| Price To Book | 0.40 X | ||||
| Price To Sales | 7.38 X | ||||
| Revenue | 12.6 M | ||||
| Gross Profit | 35 M | ||||
| EBITDA | (151.1 M) | ||||
| Net Income | (112.64 M) | ||||
| Cash And Equivalents | 791.86 M | ||||
| Cash Per Share | 22.26 X | ||||
| Total Debt | 6.06 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.42 X | ||||
| Book Value Per Share | 17.29 X | ||||
| Cash Flow From Operations | (103.76 M) | ||||
| Earnings Per Share | (3.18) X | ||||
| Market Capitalization | 258.29 M | ||||
| Total Asset | 667.59 M | ||||
| Retained Earnings | 124.63 M | ||||
| Working Capital | 510.64 M | ||||
About Iteos Therapeutics Performance
Assessing Iteos Therapeutics' fundamental ratios provides investors with valuable insights into Iteos Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Iteos Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (199.56) | (209.53) | |
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.18) | (0.19) |
Things to note about Iteos Therapeutics performance evaluation
Checking the ongoing alerts about Iteos Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Iteos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Iteos Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 12.6 M. Net Loss for the year was (112.64 M) with profit before overhead, payroll, taxes, and interest of 35 M. | |
| Iteos Therapeutics currently holds about 791.86 M in cash with (103.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 22.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: ITOS stock touches 52-week low at 7.09 amid market challenges - MSN |
- Analyzing Iteos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Iteos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Iteos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Iteos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Iteos Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Iteos Therapeutics' stock. These opinions can provide insight into Iteos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.